Active substanceChondroitin sulfateChondroitin sulfate
Similar drugsTo uncover
  • Artogistan
    solution w / m 
    GROTEKS, LLC     Russia
  • ARTRA® Chondroitin
    capsules inwards 
    Unipharm, Inc.     USA
  • Arthravir®-Inkamparm®
    solution w / m 
    TRIVIUM-XXI, LLC     Russia
  • Arthradol®
    lyophilizate w / m 
    Inkamfarm, OOO     Russia
  • ARTRADOL®
    capsules inwards 
    TRIVIUM-XXI, LLC     Russia
  • Artrafic
    ointment externally 
    ATOLL, LLC     Russia
  • DRASTOP
    solution w / m 
  • Mukosat®
    solution w / m 
  • Mukosat®
    ointment externally 
       
  • Teraflex® Hondrokrem Forte
    cream externally 
    BAYER, AO     Russia
  • Hondroguard®
    solution w / m 
  • Chondroitin
    capsules inwards 
    VERTEKS, AO     Russia
  • Chondroitin
    gel externally 
    VERTEKS, AO     Russia
  • Chondroitin
    capsules inwards 
    ATOLL, LLC     Russia
  • Chondroitin sulfate
    lyophilizate w / m 
    ELLARA, LTD.     Russia
  • Chondroitin-Akos
    ointment externally 
    SYNTHESIS, OJSC     Russia
  • Chondroitin-Akos
    capsules inwards 
    SYNTHESIS, OJSC     Russia
  • Chondroitin sulfate
    solution w / m 
    Medimeks, ZAO     Russia
  • Chondroitin sulfate
    solution w / m 
    ELLARA, LTD.     Russia
  • Chondroitin sulfate
    lyophilizate w / m 
  • Chondroitin sulfate
    solution w / m 
    BIOSINTEZ, PAO     Russia
  • Chondroxide®
    ointment externally 
    NIZHFARM, JSC     Russia
  • Chondroxide®
    pills inwards 
    NIZHFARM, JSC     Russia
  • Chondroxide®
    gel externally 
    NIZHFARM, JSC     Russia
  • Chondrolon®
    lyophilizate w / m 
  • Dosage form: & nbsp
    Gel for external use.

    Composition:

    Active substance: chondroitin sodium sulfate - 0.05 g (in terms of 100% dry matter);

    Excipients: dimethylsulfoxide (dimethoxide) 0.1 g, propylene glycol (1,2-propanediol) 0.05 g, isopropanol (isopropyl alcohol, 2-propanol) 0.05 g, ethanol (ethyl alcohol)- 0.2 g, sodium disulfite (sodium metabisulphite) 0.0005 g, methyl parahydroxybenzoate (nipagine, methylparaben) 0.0012 g, propyl parahydroxybenzoate (nipazole, propylparaben) 0.0003 g, carbomer (carbopol) 0.035 g, flavor orange (flavor of food "Orange") - 0,005 grams, water (purified water) up to 1 g.

    Description:A yellowish translucent homogeneous gel with a fruity odor.
    Pharmacotherapeutic group:Reparation of tissue stimulant.
    ATX: & nbsp

    M.01.A.X.25   Chondroitin sulfate

    Pharmacodynamics:
    Chondroxide® gel has a combined action:
    - slows the progression of osteoarthritis and osteochondrosis;
    - has analgesic effect;
    - has anti-inflammatory effect;
    - stimulates the restoration of articular cartilage;
    - improves the mobility of joints;
    - reduces swelling of the joints.

    Due to the optimal combination of gel components, the mutual enhancement of their analgesic and anti-inflammatory effects is noted. The use of the drug Chondroxide®, gel, allows to reduce the dose of non-steroidal anti-inflammatory drugs taken. Chondroxide® contains a natural component chondroitin sulfate (high molecular weight mucopolysaccharide), which takes part in the construction of cartilaginous tissue. Chondroitin sulfate:

    - improves phosphoric-calcium metabolism in cartilaginous tissue;
    - reduces the activity of enzymes that destroy cartilaginous tissue;
    - inhibits the processes of degeneration (destruction) of cartilaginous tissue;
    - stimulates the synthesis of glycosaminoglycans;
    - prevents the collapse of connective tissue.

    This leads to a decrease in soreness and increased mobility of the affected joints.
    Pharmacokinetics:Chondroxide® gel is well absorbed. According to the data obtained in experimental studies in mice using radiolabelled ZN-chondroitin sulfate, the chondroitin sulfate absorption index is 14%. Dimethylsulfoxide promotes better penetration of chondroitin sulfate through cell membranes deep into tissues. Chondroitin sulfate after applying the drug Chondroxide® gel on the skin quickly and selectively enters the joint with reaching a maximum concentration after 30 minutes and the subsequent two-phase excretion of the drug from the cartilage tissue. Completion of the rapid phase of withdrawal occurs 1 hour after application. The retention time of the drug in the joint is 5 hours.
    Indications:Degenerative and dystrophic diseases of peripheral joints and spine: treatment and prevention of osteoarthritis, osteochondrosis of the spine.
    Contraindications:Hypersensitivity to the components of the drug. Damage to the skin in the area of ​​application.
    Carefully:Pregnancy, lactation, children's age.
    Dosing and Administration:Outwardly. Chondroxide® gel is applied 2-3 times a day to the skin above the lesion and is easily rubbed with patting movements for 2-3 minutes until completely absorbed. The course of treatment is from 2-3 weeks to 2-3 months. If necessary, repeat the course of treatment.
    Side effects:Allergic reactions.
    Overdose:No cases of an overdose of the drug Chondroxide® gel have been reported.
    Interaction:Cases of interaction or incompatibility with other drugs are not known.
    Special instructions:Avoid getting the drug on the mucous membranes and open wounds. Upon contact with skin or clothing, the gel is easily washed off with water, leaving no residue. Do not use the drug without consulting a doctor during pregnancy, during lactation, in childhood.
    Effect on the ability to drive transp. cf. and fur:Chondroxide® gel does not cause sedation, psychomotor disorders and does not affect a patient's ability to engage in potentially dangerous activities requiring increased attention and speed of mental and motor reactions.
    Form release / dosage:Gel for external use 5%.
    Packaging:By 20, 25, 30, 35, 40 g in aluminum tubes or in polyethylene laminated tubes. Each tube together with instructions for medical use of the drug is placed in a pack of cardboard.
    Storage conditions:
    At a temperature of no higher than 25 ° C. Keep out of the reach of children.
    Shelf life:
    2 years. Do not use the drug after the expiry date printed on the package.

    Terms of leave from pharmacies:Without recipe
    Registration number:P N003908 / 01
    Date of registration:09.12.2009
    The owner of the registration certificate:NIZHFARM, JSC NIZHFARM, JSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp29.09.2015
    Illustrated instructions
      Instructions
      Up